

08.30 · [Coffee and Registration](#)

09.00 · [Chairman's Opening Remarks](#)

Albert Li
President and CEO
APSciences

09.15 · [In Vitro Assays for the Prediction of Nephrotoxicity](#)

Daniele Zink
Team Leader and Principal Research Scientist
Institute of Bioengineering and Nanotechnology Singapore

09.45 · [Mechanistic Kidney Model \(MechKiM\)](#)

Amin Rostami-Hodjegan,
Professor of Systems Pharmacology
School of Pharmacy and Pharmaceutical Sciences
University of Manchester

10.15 · **Networking Coffee Break**

10.45 · [Prediction and Minimisation of Risk of Drug Induced Liver Injury in Humans During Drug Development](#)

Gerry Kenna
Independent Safety Science Consultant
Fmr. Molecular Toxicologist at AstraZeneca

11.15 · [Predictivity of Different Cellular Models to Detect Human Hepatotoxic Drugs](#)

Franck Atienzar
Head, In Vitro Toxicology Unit
UCB Pharma

11.45 · **Networking Lunch**

13.15 · [A Novel Human Hepatocyte Assay for Accurate Prediction of Severe DILI Drugs](#)

Albert Li
President and CEO
APSciences

13.45 · [TRACing Cyp induction: A Novel Approach to Meet FDA Recommendations on Drug-Drug Interactions](#)

Hinnerk Boriss
CEO
Sovicell GmbH

14.15 · **Networking Coffee Break**

14.45 · [In Vitro Assays for Investigating Reactive Metabolites as a Potential Liability in Preclinical and Clinical Drug Development](#)

David Kwok
CEO
BRI Biopharmaceutical Research, Inc

15.15 · [Translational Investigation of Drug Disposition in Children](#)

Souzan Yanni
President and Founder
DMPK Consultants, Inc

15.45 · [Chair's Closing Remarks](#)

16.00 · [Close Day One](#)

08.30 · [Coffee and Registration](#)

09.00 · [Chairman's Opening Remarks](#)

Hinnerk Boriss
CEO
Sovicell GmbH

09.15 · [Incorporating IVIVE Modeling Tools with High-Throughput Screening and Exposure Data to Refine Chemical Toxicity Testing Strategies](#)

Barbara A. Wetmore
Senior Research Investigator
Institute for Chemical Safety Sciences
The Hamner Institutes for Health Sciences

09.45 · [Evidence Based Chemical Risk Assessment](#)

Andre Menache
CEO
Antidote Europe

10.15 · **Networking Coffee Break**

10.45 · [Exploration of Mitochondrial Functions to Anticipate Better Drug Toxicity](#)

Nathalie Compagnone
CEO
ICDD-sas

11.15 · [Translational Metabolic Profiles of Rodents and Children with Acetaminophen Overdose](#)

Richard Beger
Director, Biomarkers and Alternative Models Branch
National Center for Toxicological Research

11.45 · **Networking Lunch**

13.15 · [Modeling Cytochromes P450 Binding Modes to Predict P450 Inhibition, Metabolic Stability and Isoform selectivity](#)

Emanuele Carosati
Research Scientist
University of Perugia

13.45 · [Estimated Physicochemical Properties Forecast the Unexpected Renal Failure in Phase I Testing of SGX523 a c-MET Kinase Inhibitor](#)

Mike Bolger
Chief Scientist
Simulations Plus

14.15 · **Networking Coffee Break**

14.45 · [Physiologically Based PK Modeling](#)

Vikash Sinha
Clinical Pharmacology Leader
Global Clinical Pharmacology
Johnson and Johnson Pharmaceutical Research and Development.

15.15 · [In Vitro to Human In Vivo Translation – Proarrhythmic Potency of Dofetilide](#)

Sebastian Polak
Principal Scientist
Simcyp Ltd.
Jagiellonian University Krakow

15.45 · [Chair's Closing Remarks](#)

16.00 · [Close of Day Two and Conference](#)